Aclaris Therapeutics (FRA:8AT) Other Operating Expense : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Other Operating Expense?

Aclaris Therapeutics's Other Operating Expense for the three months ended in Dec. 2024 was €0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Aclaris Therapeutics's quarterly Other Operating Expense increased from Jun. 2024 (€-0.00 Mil) to Sep. 2024 (€0.00 Mil) but then declined from Sep. 2024 (€0.00 Mil) to Dec. 2024 (€0.00 Mil).

Aclaris Therapeutics's annual Other Operating Expense declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€-0.00 Mil) and declined from Dec. 2023 (€-0.00 Mil) to Dec. 2024 (€-0.00 Mil).

Aclaris Therapeutics Other Operating Expense Historical Data

The historical data trend for Aclaris Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Other Operating Expense Chart

Aclaris Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

Aclaris Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Aclaris Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Aclaris Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

ACRS:USA 0H8T:UK

Address

701 Lee Road, Suite 103, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics Headlines

No Headlines